{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:45Z","timestamp":1740144165489,"version":"3.37.3"},"reference-count":2,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40273-022-01186-y","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T18:05:25Z","timestamp":1664215525000},"page":"1013-1014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Authors\u2019 Reply to Comment on \u201cCost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison Between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine\u201d"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5720-5291","authenticated-orcid":false,"given":"Joke","family":"Bilcke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Beutels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"1186_CR1","doi-asserted-by":"publisher","unstructured":"Giannelos N, Lib\u00e9r\u00e9e Nishimwe M, Lecrenier N. Comment on Cost-effectiveness analysis of herpes zoster vaccination in 50- to 85-year-old immunocompetent Belgian cohorts: a comparison between no vaccination, the adjuvanted subunit vaccine, and live-attenuated vaccine. Pharmacoeconomics. 2022.  https:\/\/doi.org\/10.1007\/s40273-022-01184-0.","DOI":"10.1007\/s40273-022-01184-0"},{"issue":"4","key":"1186_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40273-021-01099-2","volume":"40","author":"Z Pieters","year":"2022","unstructured":"Pieters Z, Ogunjimi B, Beutels P, Bilcke J. Cost-effectiveness analysis of herpes zoster vaccination in 50- to 85-year-old immunocompetent Belgian cohorts: a comparison between no vaccination, the adjuvanted subunit vaccine, and live-attenuated vaccine. Pharmacoeconomics. 2022;40(4):461\u201376.","journal-title":"Pharmacoeconomics"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01186-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01186-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01186-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T09:57:05Z","timestamp":1665050225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01186-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":2,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1186"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01186-y","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"assertion":[{"value":"28 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported in part by Research Foundation-Flanders (JB), the Methusalem financing program of the Flemish government (ZP). The funding agreements ensured the authors\u2019 independence in designing the study, interpreting the data, and writing and publishing the report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"In 2019, P.B. participated in four half-day meetings organized by Pfizer Belgium. These meetings led to the development of a summary paper that was published in 2020 (Annemans et al., Value in Health 2020). For his participation, the University of Antwerp received compensation. P.B. received no personal fee for his participation. The University of Antwerp received grant money from the European Commission\u2019s IMI programme (RESCEU; 2017\u20132021) to fund research on RSV conducted in The Centre for Health Economics Research & Modelling Infectious Diseases (CHERMID), which P.B. heads. The IMI programme involves many pharmaceutical companies in a public\u2013private partnership. CHERMID also collaborated with the Centre for the Evaluation of Vaccination on a study on pneumococcal carriage in children (2015\u20132019), and that study was supported by a grant from Pfizer. In the period 2009\u20132019, the University of Antwerp received for its part-time \u201cchair in evidence-based vaccinology\u201d unrestricted grants from Pfizer and GSK. P.B. is promotor of the chair, but not the chair holder. By definition, the research agenda supported by the chair holder is determined and executed completely independent from the sponsors. The chair is no longer supported by private sponsors since January 2020.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"PB and JB prepared and approved the final version of the letter.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}